UroGen Pharma Reports 35% Sequential Revenue Growth for ZUSDURI in Q3 2026
UroGen Pharma Ltd. (URGN) reported strong third-quarter 2026 results, driven by the commercial performance of its product, ZUSDURI. The company achieved $68 million in net product revenue, marking a significant 35% sequential increase compared to the previous quarter. Management expressed confidence in the company's long-term financial trajectory, projecting that UroGen will achieve profitability and positive cash flow by the fourth quarter of 2026. The leadership noted that underlying commercial trends for their core product continue to strengthen.
Tickers: $URGN
Topics: earnings report product revenue quarterly results revenue growth
Read the full article at Seeking Alpha
Part of the story UroGen Pharma Reports Strong Revenue Growth Driven by Zosturi Sales (7 articles)